(4-苄基哌嗪-1-基)-(1H-吲哚-5-基)甲酮 | 353522-46-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: (4-苄基哌嗪-1-基)-(1H-吲哚-5-基)甲酮
• 英文名称: N-benzyl-N'-(5-indolylcarbonyl)piperazine
• 英文别名: 4-benzylpiperazinyl-indole-5-carboxamide；(4-benzylpiperazin-1-yl)(1H-indol-5-yl)methanone；(4-benzylpiperazin-1-yl)-(1H-indol-5-yl)methanone
• CAS: 353522-46-0
• 化学式: C₂₀H₂₁N₃O
• 分子量: 319.406
• InChiKey: FNQKXOYJSHQLHE-UHFFFAOYSA-N

物化性质

• 熔点：
  87.5 °C
• 沸点：
  529.8±45.0 °C(Predicted)
• 密度：
  1.246±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  39.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  吲哚-5-羧酸 、 1-苄基哌嗪 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以257 mg的产率得到(4-苄基哌嗪-1-基)-(1H-吲哚-5-基)甲酮
  参考文献：
  名称：

  Indole-based heterocyclic inhibitors of p38α MAP kinase: designing a conformationally restricted analogue

  摘要：

  p38alpha, Mitogen Activated Protein Kinase (MAP kinase) is an intracellular soluble serine threonine kinase. p38alpha kinase is activated in response to cellular stresses, growth factors and cytokines such as interleukin-1 (IL- 1) and tumor necrosis factor alpha (TNF-alpha). The central role of p38alpha activation in settings of both chronic and acute inflammation has led efforts to find inhibitors of this enzyme as possible therapies for diseases such as rheumatoid arthritis, where p38alpha activation is thought to play a causal role. Herein, we report structure-activity relationship studies on a series of indole-based heterocyclic inhibitors that led to the design and identification of a new class of p38alpha inhibitors. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00653-x

文献信息

• Biologically Active Compounds through Catalysis: Efficient Synthesis ofN-(Heteroarylcarbonyl)-N′-(arylalkyl)piperazines
  作者：Kamal Kumar、Dirk Michalik、Ivette Garcia Castro、Annegret Tillack、Alexander Zapf、Michael Arlt、Timo Heinrich、Henning Böttcher、Matthias Beller

  DOI：10.1002/chem.200305327

  日期：2004.2.6

  practical route for the synthesis of new biologically active 5-HT(2 A) receptor antagonists has been developed. In only three catalytic steps, this class of central nervous system (CNS) active compounds can be synthesized efficiently with high diversity. As the initial step, an anti-Markovnikov addition of amines to styrenes provides an easy route to N-(arylalkyl)piperazines, which constitute the core structure

  已经开发了一种合成新的具有生物活性的5-HT（2 A）受体拮抗剂的实用途径。在仅三个催化步骤中，这类中枢神经系统（CNS）活性化合物可以高效，高度多样性地合成。作为第一步，胺向苯乙烯的反马尔科夫尼科夫加成法提供了一条通往N-（芳基烷基）哌嗪的简便方法，后者构成了活性分子的核心结构。在此，即使在室温下，苯乙烯与苄基哌嗪的碱催化的加氢胺化反应也以高收率进行。催化脱苄基作用后，游离胺已成功地用不同的芳族和杂芳族卤化物和一氧化碳进行羰基化，以良好或优异的收率得到所需化合物。两个关键的反应，
• Medicament for treatment of liver cancer
  申请人：Zender Lars

  公开号：US10441577B2

  公开（公告）日：2019-10-15

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

  本发明提供了一种药物组合物，该组合物由索拉非尼与一种特异性激酶抑制剂组合而成，作为治疗或预防肝癌的药物。
• MEDICAMENT FOR TREATMENT OF LIVER CANCER
  申请人：Zender Lars

  公开号：US20150079154A1

  公开（公告）日：2015-03-19

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.